HIV resistance to reverse transcriptase inhibitors

Biochemical Pharmacology

Volumn 47, Issue 2, 1994, Pages 155-169

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

combination chemotherapy; dideoxynucleosides; human immunodeficiency virus; non nucleoside reverse transcriptase inhibitors; reverse transcriptase inhibitors; virus drug resistance

Indexed keywords

1 [(2 HYDROXYETHOXY)METHYL] 6 (PHENYLTHIO)THYMINE; 2 NITROPHENYL PHENYL SULFONE; 2 PYRIDONE DERIVATIVE; 2,3 DIHYDRO 9B PHENYLTHIAZOLO[2,3 A]ISOINDOL 5(9BH) ONE; 4,5,6,7 TETRAHYDRO 5 METHYL 6 (3 METHYL 2 BUTENYL)IMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINE 2(1H) THIONE; 9 CHLORO 4,5,6,7 TETRAHYDRO 5 METHYL 6 (3 METHYL 2 BUTENYL)IMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINE 2(1H) THIONE; ALPHA ANILINOPHENYLACETAMIDE DERIVATIVE; ANTIVIRUS AGENT; BHAP DERIVATIVE; DIDANOSINE; EMTRICITABINE; IMIDAZO[2',3':6,5]DIPYRIDO[3,2 B:2',3' E][1,4]DIAZEPINE DERIVATIVE; L 737126; LAMIVUDINE; NEVIRAPINE; OXATHIIN CARBOXANILIDE DERIVATIVE; PHENYLETHYLTHIOUREATHIAZOLE; PYRROLOBENZODIAZEPINONE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; S 2720; STAVUDINE; THIAZOLOBENZIMIDAZOLE DERIVATIVE; TSAO DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIROYAL; VIRUS ENZYME; ZALCITABINE; ZIDOVUDINE;

COMBINATION CHEMOTHERAPY; CROSS RESISTANCE; DRUG RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS GENOME; VIRUS MUTATION;

ANTIVIRAL AGENTS; BENZODIAZEPINES; DIDEOXYNUCLEOSIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMAN; IMIDAZOLES; MUTATION; NEVIRAPINE; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; SUPPORT, NON-U.S. GOV'T; THYMINE;

EID: 0028120730     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(94)90001-9     Document Type: Article

References (119)

1. HIV inhibitors targeted at the reverse transcriptase
2. Broad-spectrum anti-DNA virus and antiretrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines
3. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxy-ethyl)adenine, a potent anti-human immunodeficiency virus compound
4. 9-[(2RS)-3-Fluoro-2-phosphonylmethoxypropyl] derivatives of purines: A class of highly selective antiretroviral agents in vitro and in vivo
5. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphono-methoxypropyl)-2,6-diaminopurine
6. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative
7. A novel lead for specific anti-HIV-1 agents: 1-[(2- hydroxyethoxy)methyl]-6-(phenylthio)thymine
8. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives
9. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives.
10. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor
11. Pyridinone derivatives: Specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity
12. L-696, 229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro
13. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication
14. Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: Structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H — indol — 2 — yl) — carbonyl] — 4 — [3[(1- methylethyl) -amino]pyridinyl]piperazine Monomethanesulfonate (U-90152S), a second-generation clinical candidate
15. 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide)py-rimidine (TSAO) nucleoside analogues: Highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase
16. [2′,5′-Bis-O-(tert-butyldimethylsilyl)]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide) (TSAO) derivatives of purine and pyrimidine nucleosides as potent and selective inhibitors of human immunodeficiency virus type 1
17. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α- anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase
18. The discovery and general SAR studies of a novel class of potent non-nucleoside reverse transcriptase inhibitors
19. Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase
20. Thiazolobenzimidazole: Biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor
21. Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction
22. 5-Chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase
23. Synthesis and anti-HIV activity of pyrrolo-[1,2-d]-(1,4)-benzodiazepin-6-ones
24. Imidazop[2',3':6,5]dipyrido[3,2-b:2',3'-e]-1,4-diazepines: Non-nucleoside HIV-1 reverse tran-scriptase inhibitors with greater enzyme affinity than nevirapine
25. Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2, 3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-ones and related compounds with anti-HIV-1 activity
26. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication
27. Potent and selective inhibition of human immu-nodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase
28. Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6- substituted acyclouridine derivatives
29. Structure-activity relationships of 1—[(2—hydroxyethoxy)methyl]—6—(phenylthio)—thymine analogues: Effect of substitutions at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity
30. Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)-methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents
31. Effect of human serum on the in vitro anti- HIV-1 activity of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio) thymine (HEPT) derivatives as related to their lipophilicity and serum protein binding
32. Allosteric inhibition of human immunodeficiency virus type l reverse transcriptase by tetrahydroimida-zo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione compounds
33. Common features in the interaction of tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione and 1-[(2-hydroxyethoxy)-methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptase
34. Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2′,3′-dideoxynucleoside 5′- triphosphate, tetrahydroimidazo—[4,5,1—jk][1,4] -benzodiazepin-2(1H)-thione, and 1-[(2-hydroxyeth-oxy)methyl]-6-(phenylthio)thymine derivatives
35. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis-O-(tert-butyldimethylsilyl) — β — d — ribofuranosyl]-3'-spiro-5″-(4″- amino — 1″,2″ — oxathiole — (TSAO-T)
36. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site
37. Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase
38. Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors
39. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor
40. HIV-1-specific RT inhibitors: Highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase
41. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
42. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase
43. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents
44. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine
45. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine
46. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2', 3'-dideoxycytidine confers high-level resistance to the (−)enantiomer of 2',3'-dideoxy-3'-thiacytidine
47. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)
48. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine
49. Human immunodeficiency virus type 1 po1 gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine
50. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
51. High level resistance to (−)enantiomeric 2'-deoxy-3'-thiacytidine (3TC) in vitro is due to one amino acid substitution in the catalytic site of HIV-1 reverse transcriptase
52. A cysteine at codon 215 of HIV RT confers resistance to DDC
53. in vitro selection of HIV-1 resistance to d4T
54. Sequence analysis of an HIV-1 isolate which displays unusually high-level AZT resistance in vitro
55. Sequence analysis of reverse transcriptase genes of zidovudine (AZT)-resistant and -sensitive human immunodeficiency virus type 1 strains
56. Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy
57. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects
58. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors
59. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture
60. In vitro selection and molecular characterization of human immu-nodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase
61. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+) — (5S) — 4,5,6,7 — tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5,1 — jk][1,4]benzodiazepin — 2 -(1H)thione (TIBO R82150)
62. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino arid substitutions in the reverse transcriptase
63. Human immunodeficiency virus type 1-specific [2′,5′-bis- O- (tert- butyldimethylsilyl)- β- d- ribofuranosyl]-3′- spiro- 5″- (4″- amino- 1″,2″- oxathiole- 2″, 2″- di-oxide)purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-sperific non-nucleoside analogues
64. Human immunodeficiency virus type 1 drug-resistance patterns with different 1-(2-hydroxyethoxy)methyl-6-(phenyl-thio)thymine derivatives
65. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immu-nodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors
66. Rates and patterns of in vitro resistance development of HIV-1 against a new class of non-nucleoside RT inhibitors
67. A quinoxaline derivative with high inhibitory activity against HIV-1 defines a new binding site on the reverse transcriptase
68. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combiNatlons of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy
69. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus
70. Nevirapine resistance during clinical trials
71. HIV-1 strains selected for resistance against one particular class of HIV-1-specific reverse transcriptase inhibitors may retain sensitivity to other classes of HIV-1-specific inhibitors
72. Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis
73. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleotide inhibitors
74. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific 2′,5′-bis-O-(tert-butyldimethyl-silyl)3′-spiro-5″-4″-amino-l″,2″- oxathiole-2″,2″-di-oxide)/gb-D-pentofuranosyl (TSAO) nucleoside ana-logues retain sensitivity to HIV-1-specific non-nucleoside inhibitors
75. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA
76. Drug resistance in the context of the three-dimensional structure of HIV-1 reverse transcriptase
77. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors
78. The discovery and SAR studies optimizing HIV-1 inhibiting activities of LY73497, a new class of non-nucleoside inhibitors of reverse transcriptase
79. Inhibition of wild type and mutant HIV-1 RT by a new class of non-nucleoside RT inhibitors
80. A nonnucleoside reverse transcriptaScinhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitors
81. pol Mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo
82. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors.
83. AZT resistance reversal by the non-nucleoside reverse transcriptase inhibitor α-APA R18893 in a symptomatic HIV-infected individual
84. Combination therapy with zidovudine (AZT) and didanosine (DDI) selects for non-syncytia-inducing (NSI), AZT resistant HIV-1 (HIV) strains lacking a DDI-resistance mutation
85. Combination therapy with ZDV + ddI suppresses virus load but does not prevent the emergence of HIV-1 isolates with ZDV resistance
86. In vitro Combination of AZT and ddI: Synergism of action and prevention of appearance of AZT-resistant strains
87. Ribavirin for HIV
88. 1 — β — D — Ribofuranosyl -1,2,4 — triazole — 3 — carboxa- mide (ribavirin) and 5-ethynyl-1-β-D-ribofuranosyl-imidazole-4-carbo (EICAR) markedly po-tentiate the inhibitory effect of 2′,3′-dideoxyinosine on human immunodeficiency virus in peripheral blood lymphocytes
89. Mechanism of the potentiating effect of ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficiency virus
90. HIV-1 DDI-resistance overcome with combination DDI/ribavirin
91. Alternating treatment with nevirapine and zidovudine does not prevent development of nevirapine resistance
92. combination therapy with AZT prevents selection of HIV-1 variants that are highly resistant to the nonnucleoside reverse transcriptase inhibitor L-697,661
93. Delayed emergence of resistance to L-697,661 in patients receiving concomitant zidovudine
94. Prolonged sensitivity of HIV-1 isolates to atevirdine (ATV) in a phase 1 clinical trial of ATV and zidovudine (ZDV) (ACTG 199)
95. Phase I study of atevirdine (ATV), a non-nucleoside reverse transcriptase inhibitor, given in combination with zidovudine (ZDV)
96. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy
97. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro
98. HIV and multidrug resistance
99. HIV-1 error revealed
100. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: An in vitro comparative study
101. Brief report: Primary infection with zidovudine-resistant human immunodeficiency virus type 1
102. HIV seroconversion after occupational exposure despite early prophylactic zidovudine therapy
103. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients
104. Natural resistance mutations to nevirapine, ddC and ddI in ZDV-resistant HIV-1
105. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy
106. Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay.
107. Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera
108. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates
109. Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661
110. Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS
111. in vivo prevalence of azidothymidine (AZT) resistance mutations in an AIDS patient before and after AZT therapy
112. Didanosine (ddl) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI
113. Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy
114. Development of resistance to zidovudine in HIV strains isolated from CD4 + lymphocytes and plasma during therapy
115. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study
116. Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors
117. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication
118. Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine